4128.TWO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 01:30):

Stats
Today's Volume	2.22M
Average Volume	1.58M
Market Cap	23.83B
EPS	TWD-0.890 ( 2023-09-30 )
Next earnings date	( TWD0 ) 2024-05-30
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-18.11
ATR14	TWD0.0340 (0.08%)

Volume Correlation

Long: 0.02 (neutral)

Short: 0.59 (weak)

Signal:(43.963) Neutral

Microbio Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Microbio Co., Ltd. Correlation - Currency/Commodity

-0.25
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.19
( neutral )

0.53
( weak )

0.32
( neutral )

Microbio Co., Ltd. Financials

Annual	2023
Revenue:	TWD1.59B
Gross Profit:	TWD380.42M (23.90 %)
EPS:	TWD-2.11

FY	2023
Revenue:	TWD1.59B
Gross Profit:	TWD380.42M (23.90 %)
EPS:	TWD-2.11

FY	2022
Revenue:	TWD1.72B
Gross Profit:	TWD691.30M (40.15 %)
EPS:	TWD0.270

FY	2021
Revenue:	TWD1.78B
Gross Profit:	TWD739.37M (41.49 %)
EPS:	TWD0.104

Financial Reports:

No articles found.

Microbio Co., Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Microbio Co., Ltd.

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.